Related Experiment Video

Updated: Jul 14, 2026

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

EGFR and HER-2 antagonists in breast cancer

Norma O'Donovan1, John Crown

  • 1National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland. norma.odonovan@dcu.ie

Anticancer Research
|June 28, 2007
PubMed

Insights

HER-2 targeted therapies like Trastuzumab improve outcomes for HER-2-positive breast cancer. Dual inhibitors targeting HER-2 and EGFR also show promise, though patient selection for EGFR inhibitors remains a challenge.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • HER-2 and EGFR are key drivers in breast cancer development and progression.
  • HER-2 gene amplification correlates with poor prognosis, necessitating targeted treatments.
  • HER-2 targeted therapies have revolutionized treatment for HER-2-positive breast cancer.

Purpose of the Study:

  • To review the role of HER-2 and EGFR in breast cancer.
  • To discuss the efficacy of HER-2 targeted therapies and emerging dual inhibitors.
  • To highlight challenges in predicting response to EGFR inhibitors.

Main Methods:

  • Literature review of HER-2 and EGFR in breast cancer.
  • Analysis of clinical trial data for HER-2 targeted therapies (Trastuzumab) and dual inhibitors (Lapatinib).
  • Discussion of predictive markers for EGFR inhibitor response.

Main Results:

  • Trastuzumab significantly improves prognosis in HER-2-positive breast cancer (metastatic and early-stage).
  • Dual HER-2 and EGFR inhibitor Lapatinib demonstrates promising results in HER-2-positive breast cancer.
  • EGFR inhibitors have shown limited efficacy, potentially due to challenges in patient selection.

Conclusions:

  • Targeted therapies against HER-2 have transformed breast cancer treatment.
  • Dual HER-2/EGFR inhibition offers a promising therapeutic strategy.
  • Development of predictive biomarkers is crucial for optimizing EGFR inhibitor therapy in breast cancer.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...